Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ladhani, 2016, Enter B and W: two new meningococcal vaccine programmes launched, Arch Dis Child, 101, 91, 10.1136/archdischild-2015-308928
Campbell, 2009, Meningococcal C conjugate vaccine: the experience in England and Wales, Vaccine, 27, B20, 10.1016/j.vaccine.2009.04.067
Campbell, 2015, Targeted vaccination of teenagers following continued rapid endemic expansion of a single meningococcal group W clone (sequence type 11 clonal complex), United Kingdom 2015, Euro Surveill, 20, 28, 10.2807/1560-7917.ES2015.20.28.21188
Tan, 2010, Advances in the development of vaccines against Neisseria meningitidis, N Engl J Med, 362, 1511, 10.1056/NEJMra0906357
Serruto, 2012, The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens, Vaccine, 30, B87, 10.1016/j.vaccine.2012.01.033
Tirani, 2015, Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian Routine Infant Immunisation Programme, PLoS One, 10, e0123383, 10.1371/journal.pone.0123383
Yamashiro, 2015, The role of pediatricians as key stakeholders in influencing immunization policy decisions for the introduction of meningitis B vaccine in Canada: The Ontario perspective, Can J Infect Dis Med Microbiol, 26, 183, 10.1155/2015/963940
Christensen, 2014, Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study, BMJ, 349, g5725, 10.1136/bmj.g5725
Piggot
Ladhani, 2015, Invasive meningococcal disease in England: assessing disease burden through linkage of multiple national data sources, BMC Infect Dis, 15, 551, 10.1186/s12879-015-1247-7
Farrington, 1993, Estimation of vaccine effectiveness using the screening method, Int J Epidemiol, 22, 742, 10.1093/ije/22.4.742
Donnelly, 2010, Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines, Proc Natl Acad Sci USA, 107, 19490, 10.1073/pnas.1013758107
Vogel, 2013, Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment, Lancet Infect Dis, 13, 416, 10.1016/S1473-3099(13)70006-9
Frosi, 2013, Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage, Vaccine, 31, 4968, 10.1016/j.vaccine.2013.08.006
Basta, 2016, Immunogenicity of a meningococcal B vaccine during a university outbreak, N Engl J Med, 375, 220, 10.1056/NEJMoa1514866
Brunelli, 2011, Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1, Vaccine, 29, 1072, 10.1016/j.vaccine.2010.11.064
Cartwright, 1999, Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins, Vaccine, 17, 2612, 10.1016/S0264-410X(99)00044-4
Torres, 2016